Amrutanjan Health Care Limited — PPTs, 19-05-2025: Investor Presentation

1. Financial Highlights:

Amrutanjan posted net sales of Rs. 451.82 Cr in FY25, up 7.3%, with profit after tax rising 13% to Rs. 50.83 Cr. Q4 sales grew 6.6% to Rs. 135.41 Cr, and PAT increased 11.1% to Rs. 15.18 Cr. The OTC segment, including Comfy, expanded 17.8% to Rs. 414 Cr, driven by volume gains and improved raw material costs. Operating margins improved by 58 basis points despite a 7% rise in advertisement expenses and a 24% increase in employee costs.

2. Strategic Initiatives & Growth Drivers:

Growth was broad-based across pain management, women’s hygiene, and rehydration solutions. Amrutanjan’s body pain segment grew 16%, boosted by diversified SKUs like roll-ons and sprays. Comfy pads saw 18% growth, with market penetration under 40%, signaling room for scale. Captive manufacturing for Comfy is planned by FY26-end to raise margins from 33% to 40%. Digital transformation with 60% SAP adoption is enhancing operational efficiency.

3. Business Developments:

A new ethical marketing division with 30 medical sales reps targets OTX products in southern states. Amrutanjan is entering the US Amazon marketplace for its balm via a marketing tie-up. Electro+ grew 10% despite pricing pressures from regulatory and competitive challenges in ORS.

4. Market Position & Competitive Advantage:

Backed by 125 years of heritage, Amrutanjan commands strong positioning across key categories supported by differentiated SKUs and expanding media and sampling initiatives. These efforts have improved dealer and consumer connect, strengthening market share.

5. Investor Implications:

Positive growth potential is evident from category momentum, product innovation, and efficiency gains. Margin expansion in Comfy and new market entries offer upside, while competitive and execution risks in Electro+ and OTX segments warrant close monitoring.